TY - JOUR
T1 - Core values for vaccine evaluation
AU - Timmis, James Kenneth
AU - Rigat, Fabio
AU - Rappuoli, Rino
PY - 2017/1/20
Y1 - 2017/1/20
N2 - Currently, most health economic modelling approaches tend to inadequately incorporate crucial disease-specific criteria and other attributes of benefit resulting from vaccination, which limits their utility for evaluating vaccines and, in consequence, for optimally guiding vaccine decision-making. Additionally, vaccine evaluation methods are frequently poorly standardised and non-transparent, leading to a potentially low level of accountability that can hinder acceptance of resulting decisions. To address these issues, we have considered whether it is possible to identify a set of universal vaccine-disease considerations, which we have called Core Values. To begin to identify such a set of criteria, and to establish whether strong agreement around such core values exists, we conducted two studies based on the Delphi technique. Both studies surveyed a cohort consisting of expert members of the global vaccine community with diverse professional backgrounds. Formal statistical analysis of both studies identified four attributes with strong agreement: 1. Incidence disease cases prevented per year, 2. Cost-effectiveness (including cost-benefit and cost-utility analysis), 3. High mortality disease (case-fatality-rate), and 4. Severity of target disease (risk of morbidity and mortality). These results suggest the feasibility of identifying a clear consensus on a specific set of Core Values for Vaccine Evaluation.
AB - Currently, most health economic modelling approaches tend to inadequately incorporate crucial disease-specific criteria and other attributes of benefit resulting from vaccination, which limits their utility for evaluating vaccines and, in consequence, for optimally guiding vaccine decision-making. Additionally, vaccine evaluation methods are frequently poorly standardised and non-transparent, leading to a potentially low level of accountability that can hinder acceptance of resulting decisions. To address these issues, we have considered whether it is possible to identify a set of universal vaccine-disease considerations, which we have called Core Values. To begin to identify such a set of criteria, and to establish whether strong agreement around such core values exists, we conducted two studies based on the Delphi technique. Both studies surveyed a cohort consisting of expert members of the global vaccine community with diverse professional backgrounds. Formal statistical analysis of both studies identified four attributes with strong agreement: 1. Incidence disease cases prevented per year, 2. Cost-effectiveness (including cost-benefit and cost-utility analysis), 3. High mortality disease (case-fatality-rate), and 4. Severity of target disease (risk of morbidity and mortality). These results suggest the feasibility of identifying a clear consensus on a specific set of Core Values for Vaccine Evaluation.
KW - Core values
KW - Decision-making
KW - GH2035
KW - Health policy
KW - Health Technology Assessment (HTA)
KW - MCDA
KW - Vaccine evaluation
KW - Vaccine policy
UR - http://www.scopus.com/inward/record.url?scp=85009268647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009268647&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2016.11.034
DO - 10.1016/j.vaccine.2016.11.034
M3 - Article
C2 - 28017445
AN - SCOPUS:85009268647
SN - 0264-410X
VL - 35
SP - A57-A62
JO - Vaccine
JF - Vaccine
ER -